Previous close | 8.44 |
Open | 8.50 |
Bid | 8.41 x 200 |
Ask | 8.47 x 100 |
Day's range | 8.25 - 8.56 |
52-week range | 6.06 - 14.34 |
Volume | |
Avg. volume | 666,220 |
Market cap | 459.037M |
Beta (5Y monthly) | 0.98 |
PE ratio (TTM) | 2.84 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.